Burgaz García-Oteyza, S., García García, M. C., Gómez Cañas, M., Muñoz, E., & Fernández Ruiz, J. (2019). Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease.
Citação norma ChicagoBurgaz García-Oteyza, Sonia, María Concepción García García, María Gómez Cañas, Eduardo Muñoz, y Javier Fernández Ruiz. Development of An Oral Treatment With the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease. 2019.
Citação norma MLABurgaz García-Oteyza, Sonia, et al. Development of An Oral Treatment With the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease. 2019.